Factors associated with variation in single-dose albendazole pharmacokinetics: A systematic review and modelling analysis.
<h4>Background</h4>Albendazole is an orally administered anti-parasitic medication with widespread usage in a variety of both programmatic and clinical contexts. Previous work has shown that the drug's pharmacologically active metabolite, albendazole sulfoxide, is characterised by s...
Saved in:
| Main Authors: | Charles Whittaker, Cédric B Chesnais, Sébastien D S Pion, Joseph Kamgno, Martin Walker, Maria-Gloria Basáñez, Michel Boussinesq |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-10-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0010497&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Revisiting the Loa loa microfilaremia thresholds above which serious adverse events may occur with ivermectin treatment.
by: Charlotte Boullé, et al.
Published: (2025-03-01) -
River blindness: a success story under threat?
by: María-Gloria Basáñez, et al.
Published: (2006-09-01) -
Inflammation and hemostasis in loiasis before and after ivermectin treatment: A biological pilot cross-sectional study.
by: Tristan M Lepage, et al.
Published: (2024-12-01) -
Mosquitocidal efficacy and pharmacokinetics of single-dose ivermectin versus three-day dose regimen for malaria vector control compared with albendazole and no treatment: An open-label randomized controlled trial
by: Yvonne Kamau, et al.
Published: (2024-11-01) -
Effect of Two or Six Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled Trial.
by: Joseph Kamgno, et al.
Published: (2016-03-01)